MOGAT1 (monoacylglycerol O-acyltransferase 1) catalyzes the conversion of monoacylglycerols to diacylglycerols, a critical precursor for triacylglycerol synthesis 1. The enzyme is tissue-restricted, with high expression in kidney, stomach, and adipose tissue 1, and its transcriptional regulation involves PPAR signaling pathways 1. MOGAT1 functions during fasting as a PPARα target gene, participating in hepatic metabolic adaptation to maintain energy homeostasis 2. Beyond lipid metabolism, MOGAT1 drives tumor immune evasion by sequestering fatty acids into triglycerides, fostering an immunosuppressive microenvironment and promoting resistance to immune checkpoint blockade; genetic inhibition sensitizes tumors to PD-1 therapy 3. In hepatocytes, increased MOGAT1 expression correlates with lipogenic pathways leading to steatosis, fibrosis, and hepatocellular carcinoma 4. However, MOGAT1's role in pathological obesity is complex: while it reduces preadipocyte differentiation capacity in vitro 5, adipocyte-specific knockout does not prevent diet-induced obesity 5, and MOGAT1 deletion fails to ameliorate hepatic steatosis in lipodystrophic or obese models 6. Paradoxically, MOGAT1 knockdown exacerbates hepatic ischemia/reperfusion injury despite reducing triglyceride accumulation 7, suggesting MOGAT1 is necessary for liver regeneration and protection. These findings indicate MOGAT1 has context-dependent functions beyond TAG synthesis, playing critical roles in immune evasion and metabolic stress responses.